Biogen and Eisai Report Primary CLARITY AD Results for Leqembi in Early Alzheimer's

Biogen and Eisai today announced primary results from the Phase 3 CLARITY AD trial evaluating Leqembi (lecanemab-irmb) in patients with early Alzheimer's disease. The trial met its primary endpoint, demonstrating a significant slowing of clinical decline compared to placebo at 18 months, as measured by the CDR-SB score. Leqembi also significantly reduced amyloid plaques and tau tangles.